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Broadly neutralizing antibodies (bNAbs) to HIV-1
envelope glycoprotein (Env) can prevent infection
in animal models. Characterized bNAb targets,
although key to vaccine and therapeutic strategies,
are currently limited. We defined a new site of vulner-
ability by solving structures of bNAb 8ANC195
complexed with monomeric gp120 by X-ray crystal-
lography and trimeric Env by electron microscopy.
The site includes portions of gp41 and N-linked
glycans adjacent to the CD4-binding site on gp120,
making 8ANC195 the first donor-derived anti-HIV-1
bNAb with an epitope spanning both Env subunits.
Rather than penetrating the glycan shield by
using a single variable-region CDR loop, 8ANC195
inserted its entire heavy-chain variable domain into
a gap to form a large interface with gp120 glycans
and regions of the gp120 inner domain not con-
tacted by other bNAbs. By isolating additional
8ANC195 clonal variants, we identified a more
potent variant, which may be valuable for therapeu-
tic approaches using bNAb combinations with
nonoverlapping epitopes.
INTRODUCTION
The only target of neutralizing anti-HIV-1 antibodies is the enve-
lope glycoprotein (Env) spike, a heterotrimer of gp120 and gp41
subunits. Single-cell-based antibody cloning techniques have
recently uncovered a large number of antibodies that can
potently neutralize highly diverse HIV-1 variants by targeting
Env (Burton et al., 2012; Klein et al., 2013b;Mascola andHaynes,
2013; Scheid et al., 2011; Wu et al., 2010). When transferred
passively, broadly neutralizing antibodies (bNAbs) can preventinfection by HIV-1 or simian/human immunodeficiency virus
(SHIV) in humanized mice and macaques, respectively (Burton
et al., 2012; Klein et al., 2013b; Mascola and Haynes, 2013).
Moreover, combinations of bNAbs can also suppress estab-
lished HIV-1 and SHIV infections (Barouch et al., 2013; Klein
et al., 2012; Shingai et al., 2013). It is therefore believed that
vaccines that elicit these antibodies would be protective against
HIV-1.
Most of the bNAbs characterized to date target one of four
major sites of vulnerability on HIV-1 Env: on gp120, the CD4-
binding site, V1/V2, and the base of the V3 loop; and on gp41,
the membrane-proximal external region (MPER) (Burton et al.,
2012; Klein et al., 2013b; Mascola and Haynes, 2013).
8ANC195 is among a small group of bNAbs that does not appear
to target any of these sites. Although only two of the B cells orig-
inally isolated from the 8ANC195 donor, an HIV-1 elite controller,
belonged to the 8ANC195 clone, the antibodies produced by this
clone complemented the neutralizing activity of antibodies pro-
duced by a more expanded B cell clone that targeted the CD4-
binding site (Scheid et al., 2011).
8ANC195 is classified as a bNAb because it neutralized 66%
of viruses in a diverse viral panel (Scheid et al., 2011). Like other
anti-HIV-1 bNAbs (Klein et al., 2013a; Scheid et al., 2009a),
8ANC195 is highly somatically mutated, including insertions
and deletions in the complementarity determining regions
(CDRs) and framework regions (FWRs) of its heavy chain
(HC) and light chain (LC). Although initial efforts to map the
8ANC195 epitope were unsuccessful (Scheid et al., 2011),
computational analyses of neutralization data predicted that
intact potential N-linked glycosylation sites (PNGSs) at posi-
tions 234gp120 and 276gp120 were essential for its activity
(Chuang et al., 2013; West et al., 2013). These predictions
were confirmed by evaluating the neutralization potency of
8ANC195 against mutant HIV-1 strains in vitro (Chuang et al.,
2013; West et al., 2013) and in vivo (West et al., 2013). How-
ever, the precise 8ANC195 epitope on HIV-1 Env remained
elusive.Cell Reports 7, 785–795, May 8, 2014 ª2014 The Authors 785
Figure 1. Crystal Structures of 8ANC195
Fab and 8ANC195/gp120/sCD4 Complex
(A) Superimposition of unbound (gray) and bound
(HC, purple; LC, light pink) structures of 8ANC195
Fab shown as ribbon diagrams. CDR loops
are highlighted (CDRH1/CDRL1 in red, CDRH2/
CDRL2 in green, CDRH3 in dark blue, and CDRL3
in light blue), and a ‘‘thumb’’-like loop formed by an
insertion in FWR3 is indicated. Disordered loops
are shown as dashed lines.
(B) Space-filling model (inset) and ribbon diagram
of ternary complex of 8ANC195 (HC, purple; LC,
light pink), sCD4 (teal), and 93TH057 gp120 core
(inner domain, gray; outer domain, light yellow;
bridging sheet, orange; loop D, green; loop V5,
cyan; CD4-binding loop, blue). Ordered glycans
attached to Asn234gp120 and Asn276gp120 are
shown as yellow sticks (oxygens in red and nitro-
gens in blue). Fab CDR loops are colored as in (A).
sCD4 was omitted from the right panel for clarity.
(C) Approximate locations of bNAb epitopes on a
surface representation of the gp120 core. The
epitopes of V3 and V1/V2 antibodies include re-
gions of loops (dotted lines) not present in the
gp120 core structure. CD4-binding site and
8ANC195 epitopes are outlined by black (CD4-
binding site) and magenta (8ANC195) dots.
Glycans included in the 8ANC195 epitope are
shown in magenta. Subdomains of gp120 are
colored as in (B).
See also Figure S1.RESULTS
Crystal Structures of 8ANC195 Alone and in Complex
with gp120 and CD4
To determine the epitope recognized by 8ANC195 and inves-
tigate its neutralization mechanism, we solved the crystal struc-
tures of the Fab fragment of 8ANC195 alone and complexedwith
an HIV-1 clade A/E 93TH057 gp120 core and CD4 domains 1–2
(sCD4) at 2.1 and 3.0 A˚ resolution, respectively (Figures 1A and
1B; Table S1). To reduce glycan heterogeneity, five PNGSs on
the core gp120 were removed by mutation (Asn88Glngp120,
Asn289Glngp120, Asn334Glngp120, Asn392Glngp120, and
Asn448Glngp120), and the gp120 was expressed in human em-
bryonic kidney 293S (HEK293S) GnTI/ cells, which attach
only high-mannose N-linked glycans to PNGSs, rather than a
mixture of high-mannose, complex, and hybrid-type N-linked
glycans (Binley et al., 2010; Dunlop et al., 2010).
Comparison of 8ANC195 Fab in its free versus gp120-bound
state revealed high structural similarity (root mean square devia-
tion of 0.7 A˚ for 236 Ca atoms of VH-VL) except for a 3.5 A˚
displacement of the loop connecting strands D and E in HC786 Cell Reports 7, 785–795, May 8, 2014 ª2014 The AuthorsFWR3 (Figure 1A). The CDRH1 and
CDRH3 loops were folded into hook-like
tertiary structures in free and gp120-
bound Fabs; therefore, the conforma-
tions were not induced upon binding to
gp120 (Figures 1A, 2A, and 2B). The
CDRH3 architecture differed fromCDRH3s in other antibodies, including anti-HIV-1 antibodies
with long CDR loops (Figure 2C). The CDRH1 loop conformation
was stabilized by a hydrogen bond network among backbone
atoms of CDRH1, burial of Phe30HC, and hydrogen bonds with
Asp73HC and Thr97HC (Figure 2A). CDRH3 had a complex tertiary
structure in which residues 95HC–100cHC formed a loop protrud-
ing 10 A˚ from the antibody surface, and residues 100dHC–
100kHC formed a b sheet subdomain that was stabilized by
hydrophobic stacking between His100fHC and Trp32LC and a
hydrogen bond between Met100jHC and Gln89LC (Figure 2B).
The side chain of Tyr92LC hydrogen bonded with the Gly100cHC
carbonyl oxygen, stabilizing a kink in the loop that formed
the transition between these secondary structure elements
(Figure 2B).
The complex structure showed independent binding of
sCD4 and 8ANC195 Fab to distinct sites on gp120 (Figure 1B).
sCD4 interacted with the gp120 core as in other sCD4-gp120
structures (Kwong et al., 1998) (Figure S1A); thus, its binding
was not altered by the presence of the adjacent antibody,
consistent with binding and neutralization experiments showing
no effects of CD4 addition on 8ANC195 activity (Figures S1B and
Figure 2. Conformations of 8ANC195
CDRH1 and CDRH3 Loops
(A) The hook-like conformation of CDRH1 (red) is
stabilized by burial of the hydrophobic Phe30HC
side chain and hydrogen bonds within CDRH1 and
with CDRH3 (blue) and FWR1 and FWR3 residues
(Ala24HC and Asp73HC, respectively).
(B) The CDRH3 conformation (blue) consists of a
protruding loop (residues 95HC–100cHC) and a
small b sheet subdomain (residues 100dHC–
100kHC) stabilized by multiple hydrogen bonds
within CDRH3 as well as with CDRH1 and CDRL3.
A hydrogen bond between Tyr92LC andGly100cHC
stabilized the bifurcation of CDRH3 into its two
subdomains. CDRH1 and CDRH3 loop backbone
atoms are shown as sticks, and side chains of
residues important for stabilizing the loop con-
formations are shown as sticks (involved in
direct contacts) or lines (backbone involved in
contacts). Other side chains (Tyr98HC, Lys100HC,
and Trp100aHC) are shown for clarity.
(C) Comparison of CDRH3 loops in 8ANC195 and
other anti-HIV-1 bNAbs. CDRH3 residues corre-
sponding to 8ANC195HC residues 90–105 (pink) of
NIH45-46 (blue; PDB 3U7Y), PG16 (gray; PDB
4DQO), PGT121 (purple; PDB 4FQC), and PGT128
(orange; PDB 3TYG) are shown as Ca traces.S1C). sCD4 did, however, contribute to crystal packing (Fig-
ure S1D), which may explain why diffraction-quality crystals
failed to grow in its absence. In the ternary complex structure,
8ANC195 bound to a gp120 region adjacent to the CD4-binding
site, contacting mainly the gp120 inner domain, loops D and V5,
and a small patch of the gp120 outer domain (His352gp120–
Asn354gp120) (Figures 1B and 1C).
8ANC195 Fab bound gp120 core exclusively with its HC, using
residues in FWRs and its three CDR loops to form an extensive
interface (3,747 A˚2 total buried surface area; 1,347 A˚2 HC-Cell Reports 7, 785gp120 protein contacts; 2,400 A˚2 HC-
gp120 glycan contacts) (Figures 1B, 3,
and S2; Table S2). A loop in FWR3HC,
consisting of somatically mutated resi-
dues and extended by a four-residue
insertion, reached like a thumb into the
pocket formed by loops D and V5 and
outer-domain residues 352gp120–
358gp120 (Figures 1A, 1B, 3A, and S2B).
Deletion of the FWR3 insertion that re-
sults in the protruding ‘‘FWR3HC thumb’’
abrogated neutralization activity of
8ANC195 (Figure S1E). CDRH1 and
CDRH3 contacted the gp120 inner
domain (Figures 3B and S2B), contrib-
uting to a 1,347 A˚2 interface between
the 8ANC195 HC and gp120 protein res-
idues. The CDRH1 and CDRH3 loop con-
formations, conserved in the free Fab
(Figures 1A, 2A, and 2B), were necessary
for binding gp120 because extendingthese loops would result in clashes with gp120. The resulting
antibody-combining site was exquisitely suited to contacting
portions of the inner domain of gp120 not targeted by other
bNAbs (Figure 1C).
The 8ANC195 Fab also made extensive interfaces with gly-
cans attached to Asn234gp120 (buried surface area, 1,645 A˚
2)
and Asn276gp120 (buried surface area, 755 A˚
2), consistent with
its dependence on these PNGSs for neutralization (Chuang
et al., 2013;West et al., 2013). Together with CDRH2, somatically
mutated FWR residues in strands B, C00, D, and E contributed to–795, May 8, 2014 ª2014 The Authors 787
Figure 3. Contacts Made by 8ANC195 HC
with gp120 Protein Residues and Glycans
Labels for gp120 protein and glycan residues are
italicized. Hydrogen bonds are shown as dashed
yellow lines.
(A) FWR3HC loop contacts with loop D (green),
loop V5 (light blue), and outer-domain loop
(yellow).
(B) 8ANC195 HC CDRH1 (red) and CDRH3 (blue)
contacts with gp120 inner domain (gray).
(C) Buried surface area between the Asn234gp120
glycan (transparent surface with glycan residues
shown as sticks) and 8ANC195 (HC FWR resi-
dues in purple and CDRH2 in green). Antibody
atoms buried by glycan interactions are shown as
surfaces.
(D) Buried surface area between the Asn276
glycangp120 (transparent surface with glycan resi-
dues shown as sticks) and 8ANC195 (HC FWR
residues in purple and CDRH1 in red). Antibody
atoms buried by glycan interactions are shown as
surfaces.
(E) Top: contacts made by 8ANC195 HC
FWR residues (purple) and CDRH2 (green) with
Asn234gp120 glycan (orange). Glycan and pro-
tein residues involved in hydrogen bonds are
shown as sticks. Bottom: schematic representa-
tions of ordered high-mannose glycans on
Asn234gp120 and Asn276 gp120 (bottom).
See also Figure S2.an extensive interface with the Asn234gp120-associated N-
glycan (usually high mannose in native HIV-1 Envs; Go et al.,
2011) that involved ten sugarmoieties, including specific interac-
tions with terminal mannose residues (Figures 3C, 3E, and S2C–
S2H). Although Man5GlcNAc2 glycans comprise the majority of
N-glycans on gp120 proteins produced in GnTI/ cells, Man6-9
GlcNAc
2
have also been found (Dunlop et al., 2010), and the
D1,D3-Man8GlcNAc2 structure of the Asn234gp120-associated
N-glycan was verified by simulated annealing omit maps (Fig-
ures S3E and S3H). A two-residue deletion at the CDRH2–
FWR3HC boundary compared to the germline sequence
permitted these interactions because the longer loop would
clash with inner-domain residue Asn234gp120 and its neighbors.
The Asn276gp120 glycan (a complex-type N-glycan in native
HIV-1 Envs [Binley et al., 2010; Go et al., 2011], but high
mannose in the crystallized gp120) was wedged between
8ANC195 and sCD4, where it contacted FWR residues in strands
A and B and the N-terminal portion of CDRH1, forming an inter-
face involving only the core pentasaccharide common to both
high-mannose and complex-type N-glycans (Figures 3D, S2F,
and S2G). Recognition of the common core pentasaccharide
has been suggested to be an adaptation evolved by glycan-
dependent bNAbs such as PGT121 to recognize both com-
plex-type and high-mannose glycans at a particular PNGS on
Env (Mouquet et al., 2012). In the case of the 8ANC195 interac-
tion with the Asn276gp120 glycan, modeling indicates that the
core fucose of a complex-type N-glycan could be accommo-
dated by the antibody (Figure S3I); thus, 8ANC195 may also
exhibit promiscuous recognition of certain N-glycans.
The 8ANC195 HC was bracketed by the Asn234gp120 and
Asn276gp120 glycans in a manner analogous to interactions of788 Cell Reports 7, 785–795, May 8, 2014 ª2014 The AuthorsHIV-1 antibodies that penetrate the Env glycan shield, such
as PG16 (interactions with Asn160gp120 and Asn156gp120/
Asn173gp120 glycans) (Pancera et al., 2013), PGT128 (with
Asn301gp120 and Asn332gp120 glycans) (Pejchal et al., 2011),
and PGT121 (with Asn332gp120 and Asn137gp120 glycans) (Julien
et al., 2013a, 2013b;Mouquet et al., 2012) (Figure 4). However, in
contrast to these antibodies, 8ANC195 contactswith gp120were
made exclusively by its HC; indeed, 33%of 8ANC195 VH domain
residues not buried at the LC interface contacted gp120. In sum-
mary, the 8ANC195-gp120 structure demonstrated that
8ANC195 recognizes a previously undescribed epitope involving
the Asn234gp120 and Asn276gp120 glycans, the gp120 inner
domain, and loops D and V5, which would be adjacent to gp41
in Env trimer (Julien et al., 2013a; Lyumkis et al., 2013).
EM Reconstruction of 8ANC195 Bound to Soluble Env
Trimer
To investigate portions of the 8ANC195 epitope beyond the
gp120 core, including potential contacts with gp41, we used
negative stain single-particle electron microscopy (EM) to deter-
mine the structure of 8ANC195 Fab bound to a soluble HIV-1 Env
trimer with SOSIP mutations derived from strain BG505 (Figures
5A and S3) (Julien et al., 2013a; Lyumkis et al., 2013; Sanders
et al., 2013). Independent docking of the BG505 Env trimer
structure (Protein Data Bank [PDB] 4NCO) (Julien et al., 2013a)
and 8ANC195 Fab resulted in a model wherein the Fab con-
tacted both gp120 and gp41 within a single protomer (Figures
5A and S3). As expected from the lack of gp41 in the complex
crystal structure and the low resolution of the EM structure, a
small difference in Fab placement was observed between the
two structures (Figures S3D and S3E). The EM model placed
Figure 4. Comparison of Glycan-Depen-
dent bNAbs
8ANC195 is bracketed by two glycans
(Asn234gp120 glycan in orange; Asn276gp120
glycan in yellow) in the 8ANC195 Fab/gp120/
sCD4 complex structure (left panels). For com-
parison, crystal structures of PG16 (gray, middle
panels; PDB 4DQO) bound to a V1/V2 loop scaf-
fold and PGT128 (blue, right panels; PDB 3TYG)
bound to a V3 loop scaffold are shown with (A) the
antibody HCs aligned to the 8ANC195 HC or (B)
an alternative view showing their interactions with
bracketing glycans (for PG16, Asn160gp120 glycan
is in teal, and Asn172gp120 glycan is in light cyan;
for PGT128, Asn301gp120 glycan is in pink, and
Asn332gp120 glycan is in purple). The proteins are
shown as ribbon diagrams and the glycans as
stick representations.the CDRL1, CDRL2, and portions of FWR3LC and CDRH3 in
close proximity to the HR2 helix of gp41 (Figure 5B). Although
gp41 residues were not definitively identified in the trimer crystal
structure (Julien et al., 2013a), based on the assignment of the
HR2 C terminus as Gly664gp41 (Lyumkis et al., 2013), the kink
in the HR2 helix was assigned as Asn637gp41 (Figures 5B and
S4), the asparagine of a highly conserved PNGS. This assign-
ment was consistent with mapping of gp41 residues 651–664
to the end of a helix at the base of the Env trimer, as determined
by difference mapping to determine the position of residue
650gp41 (Lyumkis et al., 2013). By counting backward from resi-
due 650gp41, the kink in the HR2 helix can be assigned as residue
Asn637gp41. In addition, although the glycan at Asn637gp41 was
not built into the model for the 4.7 A˚ crystal structure of the
BG505.SOSIP trimer (Julien et al., 2013a), difference Fourier
maps calculated using the PDB 4NCO structure factors showed
electron density for the first GlcNAc of this glycan (Figure S3G).
The 8ANC195-Env trimer EM model predicted that the
Asn637gp41-linked glycan and adjacent amino acid residues on
HR2 interacted with 8ANC195 CDRH3, CDRL1, and CDRL2.
Despite the predicted contacts with the Asn637gp41-linked
glycan, a mutant YU2 pseudovirus lacking the glycan
(Asn637gp41Gln) did not show decreased sensitivity to
8ANC195 (Table S3). However, the gp120 portion of the
8ANC195 epitope is so extensive that it could mask or com-
pensate for contributions made by a smaller gp41 portion of
the epitope. In addition, the effects of removing a glycan at an
antibody-antigen interface can be unpredictable. For example,
the VRC01-like bNAbs contact Asn276gp120 on Env (Diskin
et al., 2013), yet viral strains and mutants that do not containCell Reports 7, 785–the glycan can show increased, rather
than decreased, sensitivity in neutraliza-
tion assays (Li et al., 2011).
Light Chain Involvement in
Neutralization of HIV-1 by
8ANC195
The EM reconstruction highlighted a po-
tential role for 8ANC195 LC contacts togp41. To assess LC contacts with trimeric Env, we tested chi-
meras consisting of the 8ANC195 HC paired with different LCs
in neutralization and binding assays. The chimeras included a
full germline LC, a mature LC with individual CDR loops reverted
to their germline sequences or CDRL3 partially mutated to ala-
nines, or the LC from the CD4-binding site antibody 3BNC117
(Figure 6A). As expected from the crystal structure in which all
gp120 contacts were made by the 8ANC195 HC, the chimeras
bound normally to full-length 93TH057 and YU2 gp120s (Fig-
ure 6B; Table S3); thus, changes in the LC did not disrupt the
HC portion of the antibody-combining site.
In contrast to gp120 binding, neutralization potencies as-
sayed against native Env spike trimers were decreased by
changes in the 8ANC195 LC. For example, reverting CDRL1
and CDRL2 sequences to germline precursor sequences
(changing 3 of 7 and 3 of 3 residues, respectively) almost
completely abrogated neutralization of YU2, an 8ANC195-sen-
sitive strain. Changes to CDRL3 led to a moderate reduction
in neutralization potency, as did substituting the 3BNC117 LC
for the cognate LC (Figure 6B; Table S3). A chimeric immuno-
globulin G (IgG) with one of the most conservatively substituted
LCs (Thr-Gly-Asn, mature CDRL1 containing a one-residue
insertion, reverted to Ser-Ser, germline CDRL1) displayed un-
changed binding to gp120, yet showed reductions in neutraliza-
tion potency of up to 250-fold. Similarly, conservative changes
in CDRL2 (Arg-Gly-Ala, the mature CDRL2, reverted to the
germline Lys-Ala-Ser sequence) caused large reductions in
neutralization potencies but had little effect on gp120 binding.
Overall, the data showed differential sensitivities of the binding
and neutralization assays to changes in the 8ANC195 LC that795, May 8, 2014 ª2014 The Authors 789
Figure 5. EM Reconstruction of 8ANC195/
Env Trimer Complex and Model of
8ANC195 LC Interactions with gp41 HR2
(A) EM reconstruction of 8ANC195 Fab/BG505
SOSIP.664. Side (left) and top (right) views of
EM density with the X-ray structures of BG505
SOSIP.664 (PDB 4NCO; gp120 in gray, and gp41
in light blue) and 8ANC195 Fab fit independently
of gp140 coordinates to the EM density (purple).
See also Figure S3.
(B) Close-up view of 8ANC195 LC/HR2 region of
EM complex structure (Fab placement is inde-
pendently placed as in A). In the left panel,
8ANC195 Fab is shown as a surface representa-
tion with highlights (CDRL1 in red, CDRL2 in
green, CDRH1 in red, and CDRH3 in blue), and
gp140 is shown as a ribbon diagram (gp120 in
gray, and gp41 in light blue). The position of
Asn637gp41 (magenta) was deduced from the
position of the C terminus of the SOSIP.664 trimer
(Gly664gp41). The right panel shows 8ANC195 HC
and LC residues (sticks) positioned to contact
HR2, which is shown as a surface representation
calculated from HR2 coordinates in PDB 4NCO
with presumptive side chains added to the poly-
alanine coordinates.
See also Figure S4.were distant from the gp120 surface, which supported the EM
results suggesting that LC, and CDRL1 and CDRL2 in particular,
contacted gp41.
Isolation of Clonal Members of the 8ANC195 Family
To further investigate Env recognition by 8ANC195, we isolated
additional members of this antibody clone from the original
donor by single-cell sorting using gp120 stabilized in the CD4-
bound conformation (2CC core) as bait (Figure S5). Of 1,536
single 2CC core-binding B cells, 10 (0.7%) were clonally related
to 8ANC195, and of these, only 4 differed slightly from the 2 pre-
viously described members (1–3 and 1–7 residue differences in
the HCs and LCs, respectively) (Figure S5). Consistent with the
limited sequence diversity, these antibodies exhibited similar
potencies to 8ANC195 in neutralization assays against a panel
of 15 Tier 2 viruses (Figure S5C; Table S4).
Reasoning that the 2CC core bait might fail to capture some
8ANC195 family members, we used clone-specific primers to
amplify 8ANC195 variants from purified populations of CD19+
IgG+ memory B cells (Figure S6). We obtained 128 HC and
100 LC sequences that were clonally related to 8ANC195 and
displayed greater sequence diversity than antibodies obtained
using antigen-specific selection (Figure S6). Combinations of
the 11 HC and 11 LC genes exhibiting greatest diversity were co-
transfected in order to evaluate their neutralizing activity against
a 15-member Tier 2 virus panel. Of 67 new antibodies, 3 (4.5%)
were at least as broad and potent as 8ANC195 (Figure 6C; Table
S5). One of these, g52HCk5LC, was 5-fold more potent than
8ANC195 (neutralized 12 of 15 viruses with a mean IC50 of
0.45 mg/ml as compared to 2.3 mg/ml for 8ANC195) (Table S5),790 Cell Reports 7, 785–795, May 8, 2014 ª2014 The Authorsa potency and breadth against this virus panel that was compa-
rable to bNAbs that target nonoverlapping sites (Mouquet et al.,
2012; Wu et al., 2010), such as VRC01 (neutralized 12 of 15
viruses with a 0.56 mg/ml mean IC50), and more broad but less
potent than 10-1074 (neutralized 6 of 15 viruses with a mean of
0.09 mg/ml).
The LC was critical to the activity of the more potent g52HC
k5LC variant, as demonstrated by diminished neutralization
potencies when k5LC was swapped for either k3LC or k11LC
(Figure 6C). The weaker neutralization could be explained by
differences between k5LC and k3LC at solvent-exposed resi-
dues in CDRL2 (53LC and 54LC) and FWRL3 (64LC), and a nearby
buried residue (34LC) that may affect the structural integrity of
CDRL1. Modeling of YU2 gp41 residues into the Env trimer
structure (Julien et al., 2013a) suggested that 8ANC195 posi-
tions 53LC and 54LC were adjacent to the Asn637gp41 PNGS
(Figures S4D and S7). The improved neutralizing activity of
k5LC compared with the other newly isolated LCs was associ-
ated with small side chains at positions 34LC (Val), 53LC (Ala),
and 54LC (Ala), whereas k3LC or k11LC, which were less broadly
neutralizing when paired with identical HCs, included bulkier
and/or charged side chains that would clash with the nearby
gp41 glycan. k5LC was the only LC containing an S64RLC sub-
stitution, and this single change compared to the 8ANC195 LC
may account for the 5-fold improved potency of g52HCk5LC.
Residues in the immediate vicinity of Asn637gp41 might also
modify neutralization (a computational analysis of neutralization
panel data using the Antibody Database program (West et al.,
2013) suggested that Glu632gp41 was associated with stronger
neutralization).
Figure 6. Effects of LC Sequence Changes on 8ANC195 Neutralization Potency
(A) Sequences of LC CDRs in constructs used with 8ANC195 HC to make chimeric IgGs (left) and location of CDRs on 8ANC195 structure (right). Sequences
derived from the mature antibody are shown on a pink background; those derived from the germline precursor are shown on a gray background. The mutations
introduced into CDRL3 in glCDRL3Ala are shown on a white background.
(B) Effects of changes in 8ANC195 LC on binding to 93TH057 and YU2 gp120s and neutralization of viral strains, expressed as fold changes over results for
8ANC195 IgG. KD and IC50 values for these experiments are shown in Table S3.
(C) Heatmap showing the expression and neutralization of randomly paired HCs and LCs from the bulk sort on a Tier 2 15-virus panel. Red squares represent
average IC50 values on neutralized viral strains (arithmetic means) between 0.1 and 2 mg/ml, orange squares between 2.1 and 10 mg/ml, yellow squares between
10.1 and 14.9 mg/ml, and green squares above 15 mg/ml. White squares represent insufficient antibody expression.
See also Figures S5 and S6.DISCUSSION
8ANC195 defines a site of HIV-1 Env vulnerability that includes
gp120 glycans and portions of the gp120 inner domain not tar-
geted by other bNAbs. A single-particle EM reconstruction, sup-
ported by light chain paratope analysis, suggested that the
epitope spans gp120 and gp41 (Figure 7). As such, 8ANC195
represents a patient-derived anti-HIV-1 antibody that spans
both subunits of the Env trimer. An antibody generated by phage
display was reported to exhibit binding to gp120 as well as to a
gp41-Fc fusion protein, but it was selected in vitro for these in-
dependent binding activities, and there was no evidence that it
contacts both Env subunits simultaneously on a native Env
trimer (Zhang et al., 2012). By contrast, our structural, mutagen-esis, and neutralization results suggest that the 8ANC195
epitope spans both subunits in a native trimer. Rather than
penetrating the glycan shield using only a single CDR loop, a
strategy employed by antibodies such as PG9 and PGT128
(McLellan et al., 2011; Pejchal et al., 2011), 8ANC195 inserted
its entire HC variable region into a gap in the shield to form a
large interface, of which >50% involved contacts to gp120
glycans. The recognition of both Env subunits by 8ANC195
may facilitate neutralization by preventing conformational
changes required for gp41-mediated fusion of the host cell
and viral membranes.
8ANC195 was one of two family members of a rare B cell
clone, and the original antibody was less potent than some
bNAbs targeting the CD4-binding site (Scheid et al., 2011; WuCell Reports 7, 785–795, May 8, 2014 ª2014 The Authors 791
Figure 7. Locations of bNAb Epitopes on
HIV-1 Env Trimer
EM density map of Env trimer including MPER
(trimer map EMD-5019 [Liu et al., 2008]). showing
approximate epitope locations for antibodies
targeting the 8ANC195 epitope (purple with
Asn234gp120 and Asn276gp120 glycans shown as
spheres), CD4-binding site (red), V3 loop/
Asn332gp120 glycan (blue with Asn332gp120 glycan
shown as spheres), V1/V2 loop/Asn160gp120
glycan (green with Asn160gp120 glycan shown as
spheres), and MPER (yellow).et al., 2010) or V3 loop (Mouquet et al., 2012; Walker et al., 2011).
Although it was not possible to obtain large numbers of
8ANC195 variants by standard single-cell cloning techniques
(Scheid et al., 2009b), randomly combining HCs and LCs ob-
tained from memory B cells without antigen-specific sorting
demonstrated that the target of this antibody supported neutral-
ization activity comparable to that against the most vulnerable
sites on Env. Because 8ANC195 arose in an HIV-1-infected
donor, it is possible for the human immune system to generate
antibodies against this epitope, making it a valuable site to
include on potential immunogens. Indeed, the footprint of this
bNAb on gp120 primarily involves the inner domain, contrary to
suggestions that efforts be made to focus the antibody response
on the gp120 outer domain only (Nabel et al., 2011). Character-
ization of the potential gp120-gp41-bridging epitope highlights
the importance of using properly folded gp120-gp41 Env trimers
(Julien et al., 2013a; Lyumkis et al., 2013; Sanders et al., 2013) or
building epitope scaffolds containing the gp120 outer and inner
domains plus a portion of gp41 for immunogen design.
In addition to identifying vaccine targets, bNAbs could poten-
tially be used therapeutically in established HIV-1 infections,
especially bNAb combinations that limit escape by recognizing
nonoverlapping epitopes (Barouch et al., 2013; Klein et al.,
2012; Shingai et al., 2013). Potent variants of 8ANC195 may be
particularly valuable in this respect because the epitope does
not overlap with the targets of CD4-binding site, V1/V2 loop,
V3 loop, or MPER antibodies.EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The antibodies used in this study were produced and purified as in previously
described studies by Diskin et al. (2011). Briefly, 8ANC195 and its clonal var-
iants, 3BNC60, and chimeric antibody (mature HC/various LC; g/k combina-
tions of newly isolated 8ANC195 variants) IgGs were expressed by transiently
transfecting HEK293-6E cells with vectors containing the appropriate HC and
LC genes. Secreted IgGs were purified from cell supernatants using protein A
affinity chromatography (GE Healthcare). For neutralization assays, IgGs were
diluted to 1mg/ml stocks in 20mMTris (pH 8.0), 150mMsodium chloride (Tris-
buffered saline [TBS] buffer). 8ANC195 Fab was expressed with a 63-His tag
on the C terminus of CH1 as described for IgGs and purified using Ni
2+-NTA
affinity chromatography (GE Healthcare) and Superdex 200 16/60 size exclu-
sion chromatography (GE Healthcare).792 Cell Reports 7, 785–795, May 8, 2014 ª2014 The AuthorsA truncated gp120 from the HIV-1 strain
93TH057 containing mutations Asn88Glngp120,
Asn289Glngp120, Asn334Glngp120, Asn392Glngp120,and Asn448Glngp120 was produced by transiently transfecting HEK293-S
(GnTI/) cells adapted for growth in suspension by the Caltech Protein
Expression Center with a pTT5 vector encoding His-tagged gp120. Secreted
gp120 was captured on Ni2+-NTA resin (GE Healthcare) and further purified
using Superdex 200 16/60 size exclusion chromatography.
Soluble CD4 domains 1 and 2 (sCD4) and sCD4K75T were produced as
described previously by Diskin et al. (2010). Briefly, the pACgp67b vector en-
coding 63-His-tagged sCD4 or sCD4K75T (residues 1–186 of mature CD4) was
used to make infectious baculovirus particles using BaculoGold (BD Biosci-
ence). Protein was expressed in Hi5 cells, captured on a Ni2+-NTA column
(GE Healthcare), and further purified using Superdex 200 16/60 size exclusion
chromatography. To remove an N-linked glycan introduced by mutation in
sCD4K75T, the protein was treated with Endoglycosidase H (New England Bio-
labs) for 16 hr at 25C and then purified by Superdex 200 16/60 size exclusion
chromatography.
For complex crystallization trials, purified 8ANC195 Fab, 93TH057 gp120,
and EndoH-treated sCD4K75T were incubated at a 1:1:1 molar ratio for 2 hr
at 25C. The complex was purified by Superdex 200 10/300 size exclusion
chromatography (GE Healthcare) and the peak corresponding to 8ANC195
Fab/gp120/sCD4K75T complex concentrated to 16 mg/ml in TBS buffer. For
crystallization of 8ANC195 Fab alone, the protein was concentrated to
20 mg/ml in TBS buffer.
Purified BG505 SOSIP trimers (Julien et al., 2013a, 2013b; Sanders et al.,
2013) for EM studies were the gift of Dr. John P. Moore (Weill Cornell Medical
College).
Crystallization
Crystals of 8ANC195 Fab (space group P41212, a = 66.5 A˚, b = 66.5 A˚, and
c = 219.0 A˚; one molecule per asymmetric unit) were obtained upon mixing
a protein solution at 11 mg/ml with 0.1 M HEPES (pH 7), 20% PEG 6,000,
and 10 mM zinc chloride at 20C. Crystals were briefly soaked in mother liquor
solution supplemented with 20% ethylene glycol before flash cooling in liquid
nitrogen. Crystals of the 8ANC195 Fab/93TH057 gp120/sCD4K75T complex
(space group P212121, a = 66.5 A˚, b = 132.5 A˚, and c = 142.8 A˚; one molecule
per asymmetric unit) were obtained uponmixing a protein solution at 16mg/ml
with 14% polyethylene glycol 3,350, 0.1 M HEPES (pH 7.3), and 2% benzami-
dine HCl at 20C.Crystals were briefly soaked inmother liquor solution supple-
mented with 30% ethylene glycol before flash cooling in liquid nitrogen.
Crystallographic Data Collection, Structure Determination, and
Refinement
X-ray diffraction data for 8ANC195 Fab crystals were collected at the Argonne
National Laboratory Advanced Photon Source (APS) beamline 23-ID-D using a
MAR 300 CCD detector. X-ray diffraction data for 8ANC195 Fab/93TH057
gp120/sCD4K75T complex crystals were collected at the Stanford Synchrotron
Radiation Lightsource beamline 12-2 using a Pilatus 6M pixel detector (Dect-
ris). The data were indexed, integrated, and scaled using XDS (Kabsch, 2010).
The 8ANC195 Fab structure was solved bymolecular replacement and refined
to 2.13 A˚ resolution using an iterative approach involving refinement and veri-
fication of model accuracy with simulated annealing composite omit maps
using the PHENIX crystallography package (Adams et al., 2010), and manually
fitting models into electron density maps using Coot (Emsley and Cowtan,
2004). The final model (Rwork, 20.2%; Rfree, 24.2%) includes 3,321 protein
atoms, 15 ligand atoms, and 178 water molecules (Table S1). Of the residues,
99.54%, 0.46%, and 0.0% were in the favored, allowed, and disallowed re-
gions, respectively, of the Ramachandran plot. Disordered residues that
were not included in the model include residues 127–134 and 214–219 and
the 63-His tag of the 8ANC195 HC and residues 213–214 of the LC. The
8ANC195 Fab/93TH057 gp120/sCD4K75T complex structure was solved by
molecular replacement and refined to 3.0 A˚ resolution as described for the
Fab structure. In addition to considering I/sI and completeness of the high-
est-resolution shell (2.1% and 99.9%, respectively), we used the CC1/2 statis-
tic (Karplus and Diederichs, 2012) (correlation coefficient between two random
halves of the data set where CC1/2 >10%) to determine the high-resolution cut-
off for our data. PHENIX (Adams et al., 2010) was used to compute CC1/2
(85.4% for the highest-resolution shell and 99.8% for the entire data set), sup-
porting our high-resolution cutoff determination. To prevent phase bias, no
glycan residues were present during initial stages of refinement. Glycans
were built manually in Coot (Emsley and Cowtan, 2004) into simulated anneal-
ing composite omit maps calculated using PHENIX (Adams et al., 2010)
throughout the refinement process. The final model (Rwork, 23.5%; Rfree,
27.2%) includes 7,195 protein atoms and 408 atoms of carbohydrates and li-
gands (Table S1). Of the residues, 96.92%, 3.08%, and 0.0% were in the
favored, allowed, and disallowed regions, respectively, of the Ramachandran
plot. Disordered residues that were not included in the model include residues
126–135, 185–194, and 214–219 and the 63-His tag of the 8ANC195 HC, res-
idues 212–214 of the LC, residues 125–197 (V1/V2 substitution), 302–324 (V3
substitution), residues 396–408 (a total of 6 residues from V4), residues 492–
494 and the 63-His tag of 93TH057 gp120 and residues 106–111, 150–152,
and 178–186, and the 63-His tag of sCD4K75T.
Buried surface areas were calculated using PDBePISA (Krissinel and Hen-
rick, 2007) and a 1.4 A˚ probe. Superimposition calculations were done, and
molecular representations were generated using PyMOL (Schro¨dinger,
2011). Pairwise Ca alignments were performed using PDBeFold (Krissinel
and Henrick, 2004).
ELISAs
High-binding 96-well ELISA plates (Costar) were coated overnight with 5 mg/
well of purified gp120 in 100 mM sodium carbonate (pH 9.6). After washing
with TBS containing 0.05% Tween 20, the plates were blocked for 2 hr with
1% BSA, 0.05% Tween-TBS (blocking buffer), and then incubated for 2 hr
with 8ANC195 IgG (1 mg/ml) mixed with 1:2 serially diluted solutions of poten-
tial antibody competitors (sCD4, J3 VHH, 3BNC60 Fab, and NIH45-46 Fab) in
blocking buffer (competitor concentrations ranged from 5 to 320 mg/ml). After
washing with TBS containing 0.05% Tween 20, the plates were incubated with
horseradish peroxidase (HRP)-conjugated goat anti-human IgG antibodies
(Jackson ImmunoResearch) (at 0.8 mg/ml in blocking buffer) for 1 hr. The
ELISAs were developed by addition of HRP chromogenic substrate (TMB
solution; BioLegend), and the color development was stopped by addition of
10% sulfuric acid. Experiments were performed in duplicate.
Surface Plasmon Resonance
Experiments were performed using a Biacore T100 (Biacore) using a standard
single-cycle kinetics method. YU2 and 93TH057 gp120 proteins were primary
amine coupled on CM5 chips (Biacore) at a coupling density of 1,000 RUs, and
one flow cell was mock coupled using HBS-EP+ buffer. 8ANC195 and
chimeric IgGs were injected over flow cells at increasing concentrations
(62.5–1,000 nM), at flow rates of 20 ml/min with five consecutive cycles of
2 min association/1 min dissociation and a final 10 min dissociation phase.
Flow cells were regenerated with three pulses of 10 mM glycine (pH 2.5).
Apparent binding constants (KD [M]) were calculated from single-cycle kinetic
analyses after subtraction of backgrounds using a 1:1-bindingmodel without a
bulk reflective index (RI) correction (Biacore T100 Evaluation software). Bind-
ing constants for bivalent IgGs are referred to as ‘‘apparent’’ affinities to
emphasize that the KD values include potential avidity effects.Neutralization Assays
A TZM-bl/pseudovirus neutralization assay was used to evaluate the neutral-
ization potencies of the antibodies as described (Montefiori, 2005). Pseudovi-
ruses were generated by cotransfection of HEK293T cells with an Env
expression plasmid and a replication-defective backbone plasmid. Neutraliza-
tion assays were preformed in-house for evaluating 8ANC195 LC chimeras
(Table S3; Figure 4B) and by the Collaboration for AIDS Vaccine Discovery
core neutralization facility for testing the newly isolated 8ANC195 clonal
variants (Tables S4 and S5; Figures S5 and S6). Some of the in-house data
were derived from neutralization assays that were dispensed automatically
by a Freedom EVO (Tecan) liquid handler (IC50 values derived from manual
and robotic assays agreed to within 2- to 4-fold). In all cases, neutralization
was monitored by the reduction of a Tat-induced reporter gene (luciferase)
in the presence of a 3- or 5-fold antibody dilution series (each concentration
run in duplicate or triplicate) after a single round of pseudovirus infection in
the TZM-bl cell line (Montefiori, 2005). Nonlinear regression analysis was
used to calculate the concentrations at which half-maximal inhibition was
observed (IC50 values).
Negative-Stain EM
The BG505 SOSIP.664/8ANC195 Fab complex and grids were prepared as
described previously by Kong et al. (2013). The data were collected on an
FEI Tecnai T12 electron microscope coupled with a Tietz TemCam-F416
4k x 4k CMOS camera using the Leginon interface (Suloway et al., 2005).
Images were collected in 10 increments from 0 to 40 using a defocus
range of 0.6–0.9 mm at a magnification of 52,0003, resulting in a pixel size of
2.05 A˚ at the specimen plane. Particles were selected using DoG Picker
(Voss et al., 2009) within the Appion software package (Lander et al., 2009)
and sorted from reference-free 2D class averages using the SPARX package
(Penczek et al., 1992). An initial model was generated by common lines from
class averages using the EMAN2 package (Tang et al., 2007) and was refined
using 11,637 unbinned particles. The refinement was carried out using the
SPARX package (Penczek et al., 1994) with C3 symmetry applied. The result-
ing resolution at a 0.5 Fourier shell correlation (FSC) cutoff was 18.7 A˚ (Figures
S3B and S3C). Molecular representations were generated using Chimera (Pet-
tersen et al., 2004).
Human Samples
Human samples were collected after signed informed consent in accordance
with institutional review board-approved protocols by all participating institu-
tions. Patient 8was selected from a cohort of elite controllers that was followed
at the Ragon Institute in Boston.
Isolation of 8ANC195 Variants
Single-cell clonal variants of 8ANC195 were isolated by 2CC core-specific
single-cell sorting, followed by reverse transcription and immunoglobulin
gene amplification as described previously (Scheid et al., 2011). Immuno-
globulin genes were cloned into HC and LC expression vectors and cotrans-
fected for IgG production as described previously by Tiller et al. (2008). IgG+
CD19+ memory B cells were bulk sorted on a FACSAria III cell sorter (BD Bio-
sciences). Bulk mRNA was extracted using TRIzol (Invitrogen) and reverse
transcribed as previously described (Scheid et al., 2011). 8ANC195-related
HC and LC genes were PCR amplified using clone-specific primers. Amplifica-
tion products were gel purified and cloned into TOPO TA sequencing vectors
(Invitrogen) and expression vectors as described previously by Tiller et al.
(2008).
Phylogenetic Tree and Alignment Assembly
Phylogenetic trees were assembled using Geneious Neighbor-Joining Tree
Software. Sequence alignments were performed using DNASTAR Clustal W
alignment software.
Computational Analysis
The program Antibody Database (West et al., 2013) was used to analyze
8ANC195 neutralization panel data from Scheid et al. (2011) and (Chuang
et al. (2013). This method attempts to model the variation in neutralization
potency across strains based on a sum of terms (‘‘rules’’) corresponding toCell Reports 7, 785–795, May 8, 2014 ª2014 The Authors 793
specific residues or PNGS positions. With the free residual option dese-
lected, the analysis finds a rule corresponding to 3-fold better 8ANC195
neutralization for strains with Glu632gp41. This correlation appears to hold
across clades based on neutralization data for strains having the most favor-
able glycosylation pattern (PNGS at 234gp120 and 276gp120, and not at
230gp120) (West et al., 2013). For all clades, the residue at 632gp41 versus geo-
metric mean IC50 values for 8ANC195 on strains with the most favorable
glycosylation pattern was as follows: Glu, 0.43 mg/m (n = 53) versus Asp,
1.31 mg/m (n = 51). For separate clades, the correlations were Clade A:
Glu, 0.47 mg/ml (n = 3); Asp, 1.30 mg/ml (n = 24); Clade B: Glu, 0.18 mg/ml
(n = 15); Asp, 0.72 mg/ml (n = 6); and Clade C: Glu, 0.32 mg/ml (n = 2);
Asp, 1.31 mg/ml (n = 20).ACCESSION NUMBERS
Crystallographic atomic coordinates and structure factors have been depos-
ited in the PDB (http://www.pdb.org) for the 8ANC195 Fab (4P9M) and
8ANC195 Fab-gp120-CD4 complex (4P9H) structures. The EM reconstruction
has been deposited in the Electron Microscopy Data Bank (http://www.ebi.ac.
uk/pdbe/emdb) (EMD-2625).SUPPLEMENTAL INFORMATION
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seven figures, and five tables and can be found with this article online at
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